From Medscape Neurology

Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2019

February 28 - March 02, 2019; Dallas, Texas

February 28 - March 02, 2019 Dallas, Texas

ACTRIMS 2019 Asthma Prevalence Three Times Higher in MS A new study shows a higher prevalence of asthma among multiple sclerosis patients. Reasons for the association are unknown but shared risk factors include vitamin D deficiency and smoking.
Medscape Medical News, March 7, 2019
ACTRIMS 2019 Serum Neurofilament Light Protein Highly Anticipated Tool for MS NfL levels in the blood could represent an invaluable marker in MS prognosis, as well as an aid in treatment decision-making.
Medscape Medical News, March 5, 2019
ACTRIMS 2019 New Consensus Statement on MS Imaging Strategies The North American Imaging in Multiple Sclerosis Cooperative has released a consensus statement and summary of benefits and limitations for 17 different imaging techniques.
Medscape Medical News, March 1, 2019

ACTRIMS 2019 Sleep Apnea Common in MS-Related Fatigue
Medscape Medical News, March 8, 2019
ACTRIMS 2019 Asthma Prevalence Three Times Higher in MS
Medscape Medical News, March 7, 2019
ACTRIMS 2019 Serum Neurofilament Light Protein Highly Anticipated Tool for MS
Medscape Medical News, March 5, 2019
ACTRIMS 2019 Spinal Cord Atrophy Greater in Secondary Progressive MS
Medscape Medical News, March 1, 2019

ACTRIMS 2019 New Consensus Statement on MS Imaging Strategies
Medscape Medical News, March 1, 2019
ACTRIMS 2019 Retinal Layer Thinning in MS Advances With Disease Progression
Medscape Medical News, March 1, 2019
ACTRIMS 2019 ACTRIMS Forum to Focus on Precision Medicine in MS
Medscape Medical News, February 27, 2019

Gold Nanocrystals May Remyelinate Lesions in Multiple Sclerosis Animals treated with CNM-Au8 had improved motor function, a new study shows. Already shown safe in phase 1 trials, research with this 'new therapeutic paradigm' will soon move to phase 2, researchers say.
Medscape Medical News, Feb 04, 2018
Less Frequent Natalizumab Dosing Dramatically Reduces PML Risk Extended-interval dosing of natalizumab was associated with a 94% lower risk for progressive multifocal leukoencephalopathy vs standard dosing in patients with MS positive for anti-JC virus antibody.
Medscape Medical News, Feb 03, 2018
Is Ozanimod a Safer S1P Receptor Modulator? New safety data from the SUNBEAM and RADIANCE trials.
Medscape Medical News, Feb 07, 2018

Medscape Neurology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Previous Coverage

Related Resource